Patents by Inventor Charles Garvin
Charles Garvin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220143130Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: ApplicationFiled: November 29, 2021Publication date: May 12, 2022Inventors: Jesse M. Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Bahja Ahmed Abdi, Richard Stratton, Charles Garvin
-
Publication number: 20210401927Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: ApplicationFiled: September 15, 2021Publication date: December 30, 2021Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Patent number: 11147854Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: GrantFiled: August 7, 2019Date of Patent: October 19, 2021Assignee: Riptide Bioscience, Inc.Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Publication number: 20210077566Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: ApplicationFiled: September 22, 2020Publication date: March 18, 2021Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Publication number: 20200069765Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: ApplicationFiled: August 7, 2019Publication date: March 5, 2020Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Patent number: 10413584Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: GrantFiled: August 29, 2018Date of Patent: September 17, 2019Assignee: Riptide Bioscience, Inc.Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Publication number: 20190046601Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: ApplicationFiled: October 24, 2018Publication date: February 14, 2019Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Patent number: 10149886Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: GrantFiled: October 5, 2016Date of Patent: December 11, 2018Assignee: Riptide Bioscience, Inc.Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Publication number: 20170020956Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: ApplicationFiled: October 5, 2016Publication date: January 26, 2017Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Publication number: 20040164542Abstract: An organiser for personal story and event details comprises a cover (10), a holding mechanism (12) for holding a plurality of similar sized loose-leaf pages consisting of a title page (14), a “keeper of organiser” page (16) and a series of divider pages (18) having title strips (20) to separate different sections. The cover (10) extends over and masks the pages with at least one first pocket (22) provided on the inside of the cover (10) to receive at least one pack (24) of information pages.Type: ApplicationFiled: April 21, 2004Publication date: August 26, 2004Inventor: Charles Garvin Crawford
-
Patent number: 5325388Abstract: GaAs base optical waveguide-based structure for a neural network is discld which may form the basic functional building block of a neural architecture in which the waveguide architecture contains at least three electrically active components which are electrically isolated from each other. The waveguide parameters are such that the laser light propagating through the waveguide is a single-mode in both transverse and lateral directions. A superlattice structure is incorporated in the waveguide core and results in electroabsorption of the input laser light. An electric field is supplied to the active components in order to change the transmission properties of the core material, thus modulating the light passing through the core material.Type: GrantFiled: May 5, 1993Date of Patent: June 28, 1994Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Neelam Gupta, Charles Garvin, George Simonis
-
Patent number: 4921333Abstract: A method for producing an intensity contrast image from phase detail in a transparent phase object also removes spurious background artifacts and speckle from the light source resulting in clearer images. A laser beam or other coherent light source is directed through the transparent phase object and focused into a photorefractive hologram recording crystal where a temporary volume phase hologram is formed. Once the hologram has formed a phase conjugate beam is created and passes back through the transparent phase object and is directed to an apparatus which records an intensity background pattern consisting of coherent artifacts. The transparent phase object is then mechanically shifted or allowed to move on its own in the case of transparent living specimens. The light source is directed through the physically translated transparent phase object and focused into the photorefractive hologram recording crystal.Type: GrantFiled: January 11, 1989Date of Patent: May 1, 1990Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Philip S. Brody, Charles Garvin